NCT00252382 - Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 27, 2005

Primary Completion Date

March 5, 2007

Study Completion Date

November 29, 2007

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

SNS-595 Injection

Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.

Trial Locations (4)

27705

Duke Comprehensive Cancer Center, Duke University, Durham

37203

Sarah Cannon Research Institute, LLC, Nashville

40207

Consultants in Blood Disorders and Cancer, Louisville

85260

Premiere Oncology of Arizona, Scottsdale